REGENXBIO, Nippon Shinyaku Join For Development, Commercialization Of RGX-121, And RGX-111

(RTTNews) - REGENXBIO Inc. (RGNX) and Nippon Shinyaku announced a strategic partnership for the development and commercialization of RGX-121 for the treatment of Mucopolysaccharidosis II, also known as Hunter syndrome, and RGX-111 for Mucopolysaccharidosis I. Nippon Shinyaku will commercialize both products in the Licensed Territory and future clinical development of RGX-121 and RGX-111 will be led by REGENXBIO.

REGENXBIO will receive $110 million at closing and up to an additional $700 million if certain milestones are achieved, consisting of $40 million in potential development and regulatory milestones and $660 million in potential sales milestones. REGENXBIO will also receive meaningful double-digit royalties on net sales in the U.S. and Asia.

For More Such Health News, visit rttnews.com.